TD Asset Management Inc Purchases New Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

TD Asset Management Inc bought a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 16,400 shares of the biopharmaceutical company’s stock, valued at approximately $254,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CPRX. GAMMA Investing LLC grew its holdings in shares of Catalyst Pharmaceuticals by 72.9% during the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 819 shares during the last quarter. CWM LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 686.5% during the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 3,549 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Catalyst Pharmaceuticals in the first quarter worth approximately $154,000. Ameritas Investment Partners Inc. increased its position in Catalyst Pharmaceuticals by 6.9% during the first quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 720 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in Catalyst Pharmaceuticals during the first quarter valued at approximately $191,000. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Up 1.1 %

CPRX stock opened at $20.44 on Tuesday. Catalyst Pharmaceuticals, Inc. has a twelve month low of $11.55 and a twelve month high of $20.87. The firm has a market cap of $2.43 billion, a price-to-earnings ratio of 38.11, a PEG ratio of 3.10 and a beta of 0.75. The business’s fifty day simple moving average is $18.42 and its two-hundred day simple moving average is $16.67.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.13. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. The firm had revenue of $122.71 million for the quarter, compared to analysts’ expectations of $111.76 million. Research analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.82 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on CPRX shares. Citigroup boosted their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a report on Friday, August 9th. Truist Financial boosted their target price on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. HC Wainwright lifted their price objective on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Oppenheimer reissued an “outperform” rating and set a $29.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, June 6th. Finally, StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $29.50.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Carmen Jeffrey Del sold 36,058 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $18.42, for a total value of $664,188.36. Following the completion of the sale, the insider now owns 12,369 shares in the company, valued at $227,836.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Carmen Jeffrey Del sold 36,058 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $18.42, for a total transaction of $664,188.36. Following the completion of the transaction, the insider now directly owns 12,369 shares of the company’s stock, valued at approximately $227,836.98. The disclosure for this sale can be found here. Over the last three months, insiders have sold 201,058 shares of company stock valued at $4,018,188. 11.00% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.